Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Capital Expenditures (2016 - 2025)

Anaptysbio (ANAB) has disclosed Capital Expenditures for 10 consecutive years, with $87000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 75.42% year-over-year to $87000.0, compared with a TTM value of $87000.0 through Dec 2025, down 75.7%, and an annual FY2025 reading of $87000.0, down 75.7% over the prior year.
  • Capital Expenditures was $87000.0 for Q4 2025 at Anaptysbio, up from -$74000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.3 million in Q3 2021 and bottomed at -$74000.0 in Q3 2025.
  • Average Capital Expenditures over 5 years is $156631.6, with a median of $60000.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures plummeted 161.29% in 2022, then surged 1821.05% in 2023.
  • Year by year, Capital Expenditures stood at $14000.0 in 2021, then surged by 1150.0% to $175000.0 in 2022, then surged by 60.0% to $280000.0 in 2023, then increased by 26.43% to $354000.0 in 2024, then crashed by 75.42% to $87000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ANAB at $87000.0 in Q4 2025, -$74000.0 in Q3 2025, and $63000.0 in Q2 2025.